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Abstract
Background: Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) constitute a small KIT/
PDGFRA-WT GIST subgroup featuring DNA methylation which, although pervasive, appears nevertheless not randomly
distributed. Although often indolent, these tumors are mostly chemorefractory in aggressive cases. Promoter
methylation-induced O6-methylguanine DNA methyltransferase (MGMT) inactivation improves the efficacy of alkylating
agents in gliomas, colorectal cancer and diffuse large B cell lymphoma. MGMT methylation has been found in some
GISTs, without determining SDH status. Thirty-six GISTs were enrolled in past sarcoma trials testing alkylating agents, with
negative results. Nevertheless, a possible effect on MGMT-methylated GISTs could have escaped detection, since tested
GISTs were neither selected by genotype nor investigated for SDH; MGMT was studied in two cases only, revealing
baseline activity; these trials were performed prior to the adoption of Choi criteria, the most sensitive for detecting GIST
responses to therapy. Under these circumstances, we investigated whether MGMT methylation is preferentially found in
SDH-deficient cases (identified by SDHB immunohistochemistry) by analyzing 48 pathogenetically heterogeneous GISTs
by methylation-specific PCR, as a premise for possible investigations on the use of alkylating drugs in these tumors.
Results: Nine GISTs of our series were SDH-deficient, revealing significantly enriched in MGMT-methylated
cases (6/9–67%–, vs. 6/39–15%– of SDH-proficient GISTs; p = 0.004). The pathogenetically heterogeneous KIT/
PDGFRA-WT GISTs were also significantly MGMT-methylated (11/24–46%–, vs. 1/24–4%– of KIT/PDGFRA-mutant
cases, p = 0.002).
Conclusions: A subset of KIT/PDGFRA-WT GISTs, including their largest pathogenetically characterized
subgroup (i.e., SDH-deficient ones), is preferentially MGMT-methylated. This finding could foster a reappraisal of
alkylating agents for treating malignant cases occurring among these overall chemorefractory tumors.
Keywords: Gastrointestinal stromal tumors, Succinate dehydrogenase, O6-methylguanine DNA methyltransferase,
DNA methylation, Wild-type GIST, Molecular diagnosis
* Correspondence: riccardo.ricci@unicatt.it
1Department of Pathology, Università Cattolica del Sacro Cuore, Largo F.Vito
1, 00168 Rome, Italy
2UOC di Anatomia Patologica, Fondazione Policlinico Universitario “A.
Gemelli” IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ricci et al. Clinical Epigenetics            (2019) 11:2 
https://doi.org/10.1186/s13148-018-0594-9
Background
Gastrointestinal (GI) stromal tumors (GISTs), the most
common mesenchymal tumors of the GI tract, revealed
a heterogeneous family of tumors differing in molecular
trigger and, consequently, in pathogenesis, prognosis
and therapy [1, 2]. Their vast majority hinges upon
activating mutations of either KIT or platelet-derived
growth factor receptor alpha (PDGFRA), being often
responsive to the tyrosin-kinase (TK)-inhibitor (TKI)
imatinib. GISTs wild-type (WT) for these two genes,
including their largest pathogenetically characterized
subgroup (i.e., the succinate dehydrogenase (SDH)-defi-
cient subset), although often indolent, may behave ag-
gressively, being usually unresponsive to the TKI
therapies commonly used [3–5]. In particular, presently,
there is no specific evidence of an effective therapy for
SDH-deficient GISTs with the possible exception of
regorafenib and sunitinib for their anti-angiogenic mech-
anism of action, even though mature data are still
lacking [6, 7].
The exploitation of reduced activity of O6-methyl-
guanine DNA methyltransferase (MGMT) due to
epigenetic silencing is a promising approach for se-
lectively targeting tumors employing alkylating agents,
with reduced host toxicity. This strategy has been
shown to be effective in glioma, colorectal cancer and
diffuse large B cell lymphoma [8–11].
SDH-deficient GISTs feature pervasive DNA methy-
lation, which appears, nevertheless, to be not
randomly distributed, as evidenced by the significant
number of recurrent hypo- and hypermethylated
genomic targets found in these tumors and by the
hypermethylation of SDHC, typical of SDH-deficient
GISTs WT for SDH-A, B, C, and D genes (collect-
ively termed SDHx) but not of SDHx-mutant ones
[12–14]. Noticeably, although reported in a few
GISTs [15–17], MGMT methylation has never been
investigated in SDH-deficient cases. Trials on the use
of alkylating agents temozolomide and carmustine in
sarcomas evaluated 36 GISTs, with negative results
[18–20]. However, these GISTs were neither selected
by genotype nor, coherent with the epoch of the
studies, selected and/or investigated for SDH. More-
over, MGMT was studied in two cases only, revealing
baseline activity; the actual MGMT depletion follow-
ing administration of O6-benzylguanine, a MGMT-in-
activating substrate, was not verified [20]. Finally,
these trials were performed prior to the adoption of
Choi criteria, the most sensitive method for assessing
GIST response to therapy [21]. A possible effect of
alkylating agents on MGMT-methylated GISTs could
thus have been missed, possibly due to an inappro-
priate selection of cases and a lack of proper evalu-
ation of tumor response. Following these premises,
we analyzed whether SDH-deficient GISTs are prefer-
entially MGMT-methylated, as a precondition for
possible investigations on the use of alkylating drugs
in the treatment of these tumors.
Methods
Study population
Forty-eight GISTs, assorted so as to represent various
pathogenetic types, were retrieved from the files of the
pathology departments of the Catholic University of
Rome and of the Sant’Orsola-Malpighi Hospital of
Bologna, differing in anatomic site and morphology. All
the cases had been previously characterized by
hematoxylin/eosin staining of sections from formalin-
fixed, paraffin-embedded (FFPE) specimens; by immuno-
histochemistry (IHC) for CD117 and DOG1; and by
genetic analysis of KIT (exons 9, 11, 13, and 17) and
PDGFRA (exons 12, 14, and 18). In cases WT for these
genes, KRAS (exon 2) and BRAF (V600E) were also ana-
lyzed; previously reported protocols were followed [22–
24]. BRAF status was also analyzed in five KIT or
PDGFRA-mutant cases (noticeably, BRAF mutations
have been only exceptionally detected together with KIT
or PDGFRA ones [25]). Five GISTs (from three patients)
arose in the context of neurofibromatosis type 1 (NF1).
Tumor features are detailed in Table 1. Four cases,
including two tumors previously characterized for SDH
status, have been previously published [22, 26, 27].
SDH analysis
SDHB IHC was performed on all KIT and PDGFRA-WT
cases, irrespective of site or morphology. Although
GISTs depending on molecular triggers involving genes
other than SDHx have been consistently proved
SDHB-positive [28], we investigated for SDHB expres-
sion fifteen of such tumors in our series as a control.
Mouse monoclonal antibody to SDHB 21A11 (ABCAM,
Cambridge, MA, 1:1000) was employed. The Leica
BondMax autostainer (Leica Microsystems, Bannock-
burn, IL) was employed utilizing the BondMax avidin
biotin-free polymer-based detection system preceded by
heat-induced epitope retrieval with Leica retrieval solu-
tion (alkaline buffer), using diaminobenzine as the
chromogen. Only slides with positive internal control
(smooth muscle, endothelial, epithelial, or lymphoid
cells) were considered for analysis.
Genetic analysis of SDH subunits was performed in
SDHB-negative cases as follows. The exons of the
subunits of SDH complex were sequenced on tumor and
normal tissue using the Sanger sequencing method on
ABI 310 Genetic Analyzer (Applied Biosystems). DNA
was extracted from tumor and normal FFPE specimens
by the QIAmp DNA Micro kit (Qiagen, Milan, Italy) in
accordance with manufacturer’s recommendations.
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Briefly, FFPE slices (three 10-μm-thick slices for each
sample) were digested overnight at 56 °C in ATL buffer
with the addition of proteinase K (Qiagen). DNA extrac-
tion was then continued with QIAamp DNA micro kit
(Qiagen). Each exon was amplified with polymerase
chain reaction (PCR) amplification using specific primer
pairs, as previously reported [29]. PCR was carried out
in a total volume of 25 μl consisting in 20 ng of DNA,
10 × PCR buffer, MgCl2, dNTP, primers (10 pM each),
and 1 U FastStart DNA Taq polymerase (Roche). PCR
conditions were an initial denaturation of 95 °C for 5
min, followed by 40 cycles of 95 °C for 30 s, 52–64 °C for
30 s, and 72 °C for 30 s. PCR products were purified with
the Qiaquick PCR purification kit (Qiagen) and
sequenced on both strands using the Big Dye Termin-
ator v1.1 Cycle Sequencing kit (Applied Biosystems).
MGMT analysis
DNA extraction and bisulfite modification were per-
formed on three 10-μm slides from paraffin-embedded
tissues, as previously described [30]. The pathologic
areas selected for DNA extraction contained at least 70%
disease-specific cells. The methylation status of the GpG
islands in the promoter region of MGMT was deter-
mined as described elsewhere [31]. Briefly, bisulfite-
modified DNA (100–200 ng) was amplified in a mixture
containing 1 × PCR buffer (20-mM Tris [pH 8.3],
50-mM KCl, 1.5-mM MgCl2), deoxynucleotide triphos-
phates (0.2 mM each), primers (20 pM each), and 0.75 U
GoTaq Hot Start polymerase (Promega, Madison, Wis)
in a final volume of 25 μl. PCR conditions were an initial
denaturation of 95 °C for 8 min, followed by 35 cycles of
95 °C for 60 s, 60 °C for 60 s, and 72 °C for 60 s. PCR
products were electrophoresed in a 2.5% agarose gel,
stained with ethidium bromide, and visualized under
ultraviolet illumination (93 and 81 bp were the lengths
of the unmethylated and methylathed bands, respect-
ively). Methylation-specific PCR (MS-PCR) analysis was
performed in duplicate for all samples. Normal lympho-
cyte DNA supermethylated with SssI methyltransferase
(New England Biolabs, Beverly, Mass) and treated with
bisulfite was used as the unmethylated and methylated
control, water as a negative control, and untreated DNA
as internal PCR control.
For MGMT immunohistochemistry, mouse monoclo-
nal antibody to MGMT MT 23.2 (Thermo Fisher, Wal-
tham, MA, 1:2000) was employed. The Dako autostainer
link 48 was employed utilizing the EnVision™ FLEX+ de-
tection system (Dako, Glostrup, Denmark) preceded by
heat-induced epitope retrieval (EDTA 120°, 10 min).
Only slides with positive internal control (endothelial,
lymphoid, epithelial, or smooth muscle cells) were
considered for analysis. MGMT expression was scored
by two pathologists, blinded to tumor methylation
status, molecular, and clinical data, using a three-tiered
scale as previously reported (scores 1, 2, and 3 for < 10%,
10 to 49%, and > 50% tumor cells featuring intensely and
uniformly stained nuclei, respectively) [32].
Statistical analysis
Two-tailed Fisher’s exact tests were performed to
compare pairs of data sets using Statistica 12 software
(Statsoft Inc., Tulsa, OK).
Results
SDH analysis
To identify functional loss of the SDH complex in
GISTs, we performed SHDB immunohistochemistry
[33]. Nine GISTs were SDHB-negative. All of them were
gastric, non-NF1-related, at-least-in-part epithelioid (see
Additional file 1: Figure S1, which shows a typical
SDH-negative GIST from our series) and WT for KIT,
PDGFRA, KRAS, and BRAF. All these GISTs harbored
mutations in one of the subunits of SDH, namely, SDHA
in seven cases, SDHB in one case, and SDHC in one
case. A somatic second hit flanked a germline mutation
in three cases; in five tumors, the genetic alterations
were exclusively somatic: in two cases, homozygous
(likely due to loss of heterozygosis), in one case com-
pound heterozygous, and in two cases heterozygous; in
one case, the germline SDH status could not be investi-
gated (Table 1 and Additional file 2: Figure S2, which
shows chromatograms of the SDHx mutations found in
cases 42–48 of our series).
MGMT analysis
To ascertain whether MGMT promoter CpG islands
were methylated in GISTs, and whether MGMT
methylation pattern varied among the pathogeneti-
cally heterogeneous GIST subgroups of our series,
we analyzed MGMT by MS-PCR. MGMT was meth-
ylated in only 1 out of 24 (4%) KIT or PDGFRA-mu-
tant GISTs (namely, an exon-11-KIT-mutant case),
against 11 MGMT-methylated cases of the remaining
24 (46%) KIT/PDGFRA-WT GISTs (p = 0.002, Fisher
exact test). KRAS and BRAF were WT in all the
evaluated cases of our series, including all the KIT/
PDGFRA WT tumors. Six out of 9 (67%) and 6 out
of 39 (15%) cases revealed MGMT-methylated among
SDHB-deficient and SDHB-proficient GISTs, respect-
ively (p = 0.004, Fisher’s exact test). MGMT was
methylated in one out of the five NF1-related GISTs.
Figure 1 is a representative of the MS-PCR results
for MGMT promoter in some GISTs of our series.
Data are resumed in Table 1.
To assess the impact of MGMT methylation on
MGMT expression, we performed MGMT immunohis-
tochemistry in half of GISTs of our series. The overall
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correlation between MGMT promoter methylation and
MGMT immunohistochemical expression (score 1 vs.
scores 2–3) was good (p = 0.001, Fisher’s exact test),
although a minority of tumors showed either a
high-MGMT IHC score in the presence of MGMT
methylation or the reverse condition (Table 1, Fig. 2).
Discussion
We herein assessed MGMT methylation status in a popu-
lation of GISTs heterogeneous with respect to pathogen-
esis. Our results show that a subset of GISTs WT for KIT
and PDGFRA, including their largest pathogenetically
characterized subpopulation, i.e., the SDH-deficient ones,
is significantly enriched in MGMT-methylated cases, with
SDH-deficient GISTs featuring the highest prevalence of
this tumor variant. Thus, these subsets of GISTs, charac-
terized by a problematic clinical management in case of
malignancy because of their usual resistance to imatinib
and variable response to other drugs, appear potentially
predisposed to respond to alkylating agents.
GISTs WT for KIT and PDGFRA constitute a patho-
genetically heterogeneous tumor group accounting for
about 10–15% of GISTs [1]. Taken together, these
GISTs are characterized by an overall indolent behav-
ior [3, 4]. However, malignant cases may occur, often
accompanied by unresponsiveness to the commonly
used TKI therapies [5].
SDH-deficient GISTs, characterized by negativity at
SDHB immunostaining, constitute the largest pathogen-
etically characterized subgroup among cases WT for KIT
and PDGFRA. Their pathogenesis basically follows the
classic tumor-suppressor gene model, with both alleles
of one of the four SDH subunits inactivated in the tumor
cells, either on a mutational (often with a germline
Fig. 1 Methylation status of MGMT promoter gene (MS-PCR) in four examples of GIST. Lanes containing PCR products derived from unmethylated and
methylated alleles are marked U and M, respectively (with a length of 93 and 81 bp, in that order). GISTs 41 and 44 show a hypermethylated MGMT
promoter gene; the same gene is unmethylated in GISTs 10 and 17 (the bands present in the M lanes of these two GISTs and in both lanes of UC are
primer dimers). UC untreated control DNA, PC positive control DNA, MW molecular weight marks (100-bp ladder)
Fig. 2 MGMT protein expression assessed by IHC in six examples of GIST. At MGMT IHC, MGMT-unmethylated GISTs 43 (a), 26 (b), and 27
(c) featured nuclear staining in the majority of cells (score 3), unlike MGMT-methylated GISTs 32 (d), 31 (e), and 44 (f) (score 1).
Endothelial and lymphoid cells (the periphery of a lymphoid aggregate is evident in e, top left) act as internal positive controls. (Scale bars: 20 μm)
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component) or epigenetic (SDHC hypermethylation)
base, possibly presenting in syndromic settings (Carney
triad or Carney-Stratakis syndromes) [3, 12, 28, 34].
Their progression can be extremely slow, with reported
time lapses between primary tumor and metastasis as
long as 42 years [33], and their stage and clinical behav-
ior are often incoherent, with frequent prolonged
survival in the presence of metastases. These features,
likely caused by the metabolic disadvantage due to SDH
deficiency, can make the attribution of disease stability
to a drug effect problematic [7]. Nevertheless, SDH-defi-
cient GIST can behave aggressively, with an overall mor-
tality probably higher than 15%, with cases fatal in a few
years [28].
Imatinib, a TKI acting on several KIT and PDGFRA
isoforms, proved ineffective in SDH-deficient GISTs
[28], coherently with SDH deficiency being a trigger
independent of KIT/PDGFRA. No mature data concern-
ing the use of sunitinib in these neoplasms are available,
although a clinical benefit due to an anti-angiogenic
mechanism may occur. Of note, the rarity of SDH-defi-
cient GISTs makes investigations on pure populations of
such tumors very difficult. Consequently, clues for estab-
lishing an effective chemotherapy for this GIST subset
are often inferred from studies on KIT/PDGFRA-WT
cases, which are enriched in SDH-deficient tumors. Fol-
lowing these premises, drugs of potential interest for
treating the latter neoplasms, in part represented by
experimental molecules based on their biology, include
linsitinib, PI3K/AKT/mTOR inhibitors, nilotinib, sorafe-
nib, heat-shock protein inhibitors, chemicals targeting
hypoxia-inducible factor-1α, and demethylating agents
such as decitabine [14, 35–39]. Nevertheless, we pres-
ently do not dispose of a reliably effective drug for treat-
ing SDH-deficient GISTs, with the possible exception of
regorafenib, recently reported to induce objective
responses and durable benefit [6].
MGMT inactivation through gene methylation allows
the effective employment of alkylating agents in hetero-
geneous human tumors [8–11]. SDH-deficient GISTs
display DNA methylation (both in the presence of SDHx
mutations or not) which, although overall pervasive, is
not randomly distributed [12–14]. We therefore studied
MGMT methylation in the SDH-deficient GIST
subgroup, as a premise to possible investigations on the
employment of alkylating agents for their treatment.
We identified nine SDH-deficient GISTs, as assessed
by SDHB protein loss, all of which harboring mutations
in one of the SDH subunits (Table 1). Epigenetic inacti-
vating mechanisms, such as allelic hemimethylation, can
be hypothesized to explain the loss of SDHB protein in
the three tumors of our series lacking a detectable sec-
ond hit, bearing a heterozygous SHDx mutation; in fact,
combined heterozygous mutation and hemimethylation
have been reported in SDHx (namely, SDHC) in some
GISTs; moreover, SDHA-mutant GISTs which, despite
the absence of a detectable second hit, nevertheless
featured loss of SDHB expression have also been sig-
naled [14]. Of note, our finding of five cases lacking
germline SDHx mutations out of 8 SDHx-mutant SDH-
deficient ones whose germline could be investigated
could possibly support a relatively common occurrence
of this GIST type in the absence of a syndromic
predisposition.
In our series, all MGMT-methylated cases but one
were detected in the pathogenetically heterogeneous
group of GIST WT for KIT and PDGFRA, and
SDH-deficient GISTs were significantly enriched in
MGMT-methylated cases; noticeably, with the limita-
tions due to the small number of cases considered,
SDH-deficient GISTs featured the highest prevalence of
MGMT methylation (6/9, 67%) when compared to the
other pathogenetically characterized GIST subgroups of
our series (0/10, 0%, of PDGFRA-mutant GISTs; 1/15,
7%, of KIT-mutant GISTs; 1/5, 20%, of NF1-associated
GISTs; Table 1). Additionally, we found an overall good
correlation between MGMT methylation and MGMT
protein expression, as assessed by IHC (the discrepancy
found in a minority of cases could depend on DNA
methylation levels not enough to inhibit protein expres-
sion on the one hand, or on mechanisms affecting
protein expression alternative to DNA methylation, such
as histone modifications or post-transcriptional regula-
tion, on the other [40]). Thus, our results support the
potential predisposition to respond to alkylating agents
of a subset of the hitherto globally chemorefractory KIT/
PDGFRA WT GISTs, including their largest pathogeneti-
cally characterized subtype: SDH-deficient ones.
We do not know whether the MGMT methylation we
observed in KIT/PDGFRA-WT GISTs, including those
SDH-deficient, is due to a mechanism specifically target-
ing MGMT or not (of note, this issue would not affect the
potential therapeutic implications of the event). The DNA
methylation described in SDH-deficient GISTs, caused by
the impairment of the conversion of 5-methylcytosine to
5-hydroxymethylcytosine (required for DNA demethyla-
tion) due to the inhibition of TET DNA-hydroxylases sec-
ondary to succinate accumulation [3], could
non-specifically contribute to the enrichment in
MGMT-methylated cases we found among SDH-deficient
GISTs. Nevertheless, since, as noted above, DNA methyla-
tion in these latter tumors is not randomly distributed
[12–14], hitherto unknown gene-specific mechanisms
regulating DNA methylation, possibly similar to that
exerted by HOTAIR in some GISTs [41], are bound to
flank the non-specific DNA methylation machinery de-
scribed in SDH-deficient GISTs, and could affect MGMT
also. Conversely, to the best of our knowledge, neither
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relatively high-DNA methylation levels, nor DNA methy-
lation mechanisms, have been described in KIT/
PDGFRA-WT, SDH-competent GISTs, explaining the sig-
nificant MGMT methylation we found in these tumors.
The cases of our series were arbitrarily assorted with
the aim of investigating MGMT methylation in GIST
subgroups differing in molecular trigger; consequently,
rare GIST types such as SDH-deficient and NF1-related
ones are overrepresented with respect to population-
based series. Nevertheless, considering the known
epidemiology of GISTs [1], our finding of MGMT
methylation substantially restricted to almost half of the
investigated KIT/PDGFRA WT cases, even though these
also were arbitrarily assorted in our series, supports a
rare occurrence of this condition in GISTs, probably
accounting for < 5–10% of cases. To the best of our
knowledge, only four papers have reported on MGMT
methylation or expression in GISTs, employing hetero-
geneous methods. Two of them, both employing
MS-specific PCR, report a relatively high fraction of
MGMT-methylated GISTs, potentially challenging the
concept that MGMT methylation is a relatively rare
event in these tumors [15–17, 20]. However, one of
these papers dealt exclusively with gastric cases [15],
which are expectedly enriched in SDH-deficient GISTs,
albeit presumably not at a level to justify per se the
detected prevalence of MGMT-methylation (of note,
SDH status was not investigated, coherently with the
epoch of the study, which preceded the discovery of the
role of SDH in GIST pathogenesis [42]). The paper by
Saito and co-workers [16] overtly contrasts with our
findings in terms of expected low prevalence of
MGMT-methylated GISTs; nonetheless, all three of the
three (100%) reported cases WT for both KIT and
PDGFRA featured a methylated MGMT. Noticeably,
none of these works concerning MGMT methylation in
GISTs was population-based.
Published data on the effectiveness of alkylating agents
temozolomide and carmustine in GIST treatment,
although apparently discouraging, do not stand defini-
tively against a possible efficacy of alkylating agents
restricted to a subset of the uncommon KIT/PDGFRA
WT GISTs, including SDH-deficient ones. In fact, these
results are based on a limited number of GIST patients
recruited in past trials on sarcomas, without either
selecting the genotype or investigating the SDH status of
the tumors [18–20]. The latter event is again coherent
with the epoch of the referred studies. Moreover,
MGMT status was studied only in two of these tumors,
significantly revealing spontaneous activity and, although
O6-benzylguanine was administered with the aim of
inhibiting this enzyme, the achievement of such an effect
was not verified [20]. Finally, Choi response criteria, the
most sensitive method for detecting GIST response to
drugs [21], were not employed, once more coherently
with the epoch of the referred papers. Thus, a possible
effect of alkylating agents on a predisposed fraction of
GISTs could have so far escaped detection since (1) we
herein prove that MGMT methylation is substantially
restricted to rare subsets of these tumors, implying the
possibility that a few (or even none) of the limited num-
ber of GIST patients enrolled in the abovementioned
trials could respond to the administered therapy, and (2)
a possible response of some GISTs, bearing an inacti-
vated MGMT, could have escaped detection, given the
missed adoption of Choi criteria. This scenario could
have led to erroneously abort further studies on alkylat-
ing agents in GISTs. As confirmation of our hypothesis,
a phase 2 trial investigating a response to the drug temo-
zolomide in metastatic SDH-deficient GIST to improve
patient outcomes was recently launched and is ongoing
(ClinicalTrials.gov/NCT03556384).
Conclusions
A subset of KIT/PDGFRA-WT GISTs, including their
largest pathogenetically characterized subgroup (i.e.,
SDH-deficient GISTs), is preferentially MGMT-methy-
lated. This finding fosters a reappraisal of alkylating
agents for treating malignant cases occurring among
these overall chemorefractory tumors.
Additional files
Additional file 1: Figure S1. Microphotograph showing a SDH-
deficient GIST (case 43). (a) Tumor consisted of sheets of epithelioid
cells with eosinophilic cytoplasm (scale bar: 15 μm). (b) Tumor cells
lack cytoplasmic SDHB granular positivity, retained in non-neoplastic
cells (notice the cytoplasmic labeling of smooth muscle cells, both in
gastric muscularis propria—top left—and in a blood vessel wall—-
center—, or of scattered tumor infiltrating leukocytes and plasma
cells) (scale bar: 15 μm). (TIF 16742 kb)
Additional file 2: Figure S2. Chromatogram showing the SDHx
mutations found in GISTs (T) and in normal tissue (N) in cases 42–48.
Case 42: heterozygous SDHA exon 5 mutation in normal tissue and
homozygous in GIST. Case 43: somatic heterozygous SDHA exons 1 and
13 mutations in GIST. Case 44: somatic heterozygous SDHA exon 9
mutation in GIST. Case 45: somatic homozygous SDHA exon 10 mutation
in GIST. Case 46: somatic homozygous SDHB exon 6 mutation in GIST.
Case 47: somatic heterozygous SDHC exon 4 mutation in GIST. Case 48:
heterozygous SDHA exon 9 mutation in GIST (germline not tested). (SDHx
mutations found in cases 40 and 41 have been previously reported—see
ref. [26] of the main text). (PPTX 1802 kb)
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